eureKARE successfully hosts inaugural SynBio Day and EureKAWARDS

eureKARE successfully hosts inaugural SynBio Day and EureKAWARDS

  • Congratulations to the first eureKAWARDS pitch contest winner, Prof. Roy Bar-Ziv of the Weizmann Institute of Science
  • Thank you to all the attendees and our partners Potter Clarkson, ERS Genomics and the Neighborhood VCLS’ Innovation Center
  • eureKARE looks forward to welcoming everyone again in 2022 for the next SynBio Day

Luxembourg and Paris, France – 19 November 2021: eureKARE ("the Company"), a pioneering new company focused on financing and building next generation biotechnology companies in the disruptive fields of synthetic biology and the microbiome, concluded its successful inaugural eureKARE SynBio Day on November 10th, 2021. The event brought together over 200 stakeholders from industry, academia and investment with an interest in synthetic biology. The day was filled with impactful sessions delivered by esteemed speakers who provided industry insights to highlight the importance of synthetic biology. An expert round table also explored the challenges that need to be addressed ranging from societal views and policy, to funding and regulation.

eureKARE would like to extend its thanks to all the attendees of the inaugural SynBio Day and to our partners, Potter Clarkson, ERS Genomics and Neighborhood VCLS’ Innovation Center, for contributing to the success of the event.

The eureKARE SynBio Day also marked the culmination of the inaugural eureKAWARDS pitch contest, which searched for innovative start-up ideas in synthetic biology from Europe, the UK, and Israel. eureKARE is grateful to the team of experts from leading companies and research institutions across Europe who made up the jury that reviewed and selected the finalists for the eureKAWARDS.

The eureKAWARDS received a number of high-quality and innovative submissions from multiple countries and eureKARE would like to congratulate Prof. Roy Bar-Ziv of the Weizmann Institute of Science in Israel as the winner of the first-ever eureKAWARDS. Roy Bar-Ziv’s submission, combining physics with biology and biochip artificial cells technology, stood out to the jury owing to its scientific excellence and highly disruptive approach to diagnostics and therapeutics. As the winner, Roy will be eligible to receive free access to premium services provided by the eureKASYNBIO startup studio team and its network of validated partners for one year. He will also receive guidance and support from eureKARE’s team and broad network of validated academic and industrial professionals in synthetic biology.

Rodolphe Besserve, eureKARE CEO, commented: “I am delighted by the success of our first ever SynBio Day which exceeded our expectations. I would like to personally congratulate Roy on winning the eureKAWARDS and thank all those that participated, particularly our speakers, jury, and my colleagues who worked hard to achieve such a smooth and successful event. We are pleased to have played a role in highlighting the importance of the synthetic biology space, a critical area of research in today’s age. We hope to continue contributing to the field and I am already looking forward to SynBio Day 2022.

Special thanks from eureKARE to:


  • Jean-David Malo, Director of the Executive Agency for EIC and SMEs (EISMEA)
  • Dr. André Choulika, CEO and Board Director of Cellectis
  • Prof. Antoine Danchin, CSO of Kodikos Labs and Chairman of eureKARE SAB
  • Dr. David Bikard, CTO and Co-founder of Eligo Biosciences
  • Dr. Iordanis Arzimanoglou, EIC Programme Manager, Health and Biotechnology
  • Dr. Pamela Silver, Professor of Systems Biology at Harvard Medical School & Member of eureKARE SAB
  • Prof. Dr. Petra Schwille, Director, Cellular and Molecular Biophysics Max Planck Institute of Biochemistry
  • Dr. Siyuan Chen, CTO of Twist Bioscience

Our roundtable moderator and panelists:

Nastassia Astrasheuskaya, Financial Times, Dr. Karen Fallen, CEO, Touchlight, Anya Roy, Head of Illumina Accelerator UK, Ana Atanassova, Global Regulatory Policy, BASF AP, Prof. Darian Meacham, Maastricht University, Dr. Rodrigo Ledesma Amaro, Team Leader, Imperial College London, Fiona Mischel, Director of International Outreach, Synbiobeta, Dr. Yuval Dorfan, IDC, Israeli SynBio Institute founding director.

The eureKAWARDS Jury comprised of:

Siau Bai, Early Innovation Partnership Director for Johnson and Johnson Innovation, Marc Chevalier, Head of Bioentrepreneurship at Imagine Institute of Genetic Diseases, Sebastien Giraudier, Director of Neighborhood, VCLS Innovation Center, Neil Goldsmith, Co-founder of Evolva and Serial Entrepreneur in Synthetic biology, Aurélie Grienenberger, CBO at Eligo Bioscience, Sara Holland, Senior Associate UK and European Patent Attorney at Potter Clarkson, Richard Reschen, Associate Director Business Development & Licensing at MSD, Eric Rhodes, CEO of ERS Genomics.

The eureKARE Scientific advisory board serving as the Scientific Jury including:

Prof. Antoine Danchin, Dr. Joël Doré, Dr. Leroy Hood, Dr. Philippe Marlière, Prof. Dr. Sven Panke, Dr. Felix Rey, Dr. Pamela Silver and Dr. George Weinstock.

- End -

About eureKARE

eureKARE is a unique project development company dedicated to investing and developing next generation biotechnology companies in the cutting-edge fields of the microbiome and synthetic biology. eureKARE has a two-step investment approach to deliver long-term value creation. The Company supports translational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). The Company also intends to invest in more mature biotech companies and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field. Guided by its influential founder, Alexandre Mouradian, and a pan-European team, eureKARE has a rapidly growing portfolio of companies that have the potential to disrupt the life sciences industry.

For more information

Marina Shapochnik, Head Investor Relations

Consilium Strategic Communications
Amber Fennell, Sukaina Virji, Genevieve Wilson
+44 (0) 203 709 5000